Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

21.4%

6 terminated/withdrawn out of 28 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

9 of 18 completed trials have results

Key Signals

1 recruiting9 with results6 terminated

Enrollment Performance

Analytics

Phase 1
21(75.0%)
Phase 2
7(25.0%)
28Total
Phase 1(21)
Phase 2(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (28)

Showing 20 of 28 trials
NCT03971409Phase 2Active Not Recruiting

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Role: collaborator

NCT03170206Phase 1Completed

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Role: collaborator

NCT04074967Phase 1Active Not Recruiting

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Role: collaborator

NCT04598009Phase 2Recruiting

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Role: collaborator

NCT03231306Phase 2Completed

Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

Role: collaborator

NCT04375527Phase 2Terminated

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Role: collaborator

NCT03374254Phase 1Completed

Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)

Role: collaborator

NCT01921335Phase 1Completed

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

Role: collaborator

NCT03843775Phase 1Completed

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Role: collaborator

NCT01894672Phase 2Completed

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Role: collaborator

NCT02834364Phase 2Completed

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Role: collaborator

NCT01859026Phase 1Completed

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Role: collaborator

NCT04005144Phase 1Terminated

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Role: collaborator

NCT02384083Phase 1Completed

Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients

Role: collaborator

NCT02510001Phase 1Completed

MEK and MET Inhibition in Colorectal Cancer

Role: collaborator

NCT03158103Phase 1Completed

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Role: collaborator

NCT02089230Phase 1Terminated

MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

Role: collaborator

NCT04292119Phase 1Unknown

Lorlatinib Combinations in Lung Cancer

Role: collaborator

NCT01828034Phase 1Completed

First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma

Role: collaborator

NCT00650572Phase 1Completed

A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

Role: collaborator